Mitralign adds another $8 million to its coffers a few months after closing enrollment on a clinical trial of its mitral valve repair device.
Mitralign added more than $8 million to its coffers in an equity funding round, after closing enrollment of a clinical trial for its namesake mitral valve repair device in April.
The Mitralign system is designed to deliver via catheter at least 1 pair of anchors that, when cinched together, help restore the heart's mitral valve to its natural shape in patients with functional mitral regurgitation, according to a press release.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1pmqmXX
Cap comentari:
Publica un comentari a l'entrada